Church & Dwight pairs durable branded-consumer growth with strong cash generation, but the stock’s premium valuation keeps the call at Hold. Q1 showed solid organic growth and margin expansion, yet upside looks limited near the current fair value.
The investment thesis for Church & Dwight (CHD) rests on a durable branded-consumer portfolio, strong cash generation, and above-category growth from innovation and distribution gains. The trade-off is valuation: CHD generated $6.2B of 2025 revenue, but revenue growth was only 0.2% on the latest growth measure, while the shares carry a 32.8x trailing P/E, a 26.5x forward P/E, and a 3.1 PEG ratio.
Q1 2026 showed why the business commands a premium. Net sales rose 0.2% to $1.47B, organic sales increased 5.0%, adjusted EPS reached $0.95, and adjusted gross margin expanded 130 basis points to 46.4%. Growth was volume-led, and management reported gains across ARM & HAMMER, TheraBreath, Hero, and OxiClean.
The medium-term outlook is constructive but not aggressive. Management reaffirmed 2026 organic sales growth of 3% to 4%, adjusted EPS growth of 5% to 8%, and gross-margin expansion of about 100 basis points. Analyst estimates show EPS rising from $4.04 in 2027 to $4.78 in 2030, while the consensus target is $103.84. The $100 hold price reflects strong execution and cash flow, offset by modest reported growth, elevated valuation, debt, and commodity exposure.
Church & Dwight (CHD) is a consumer defensive company founded in 1846 and headquartered in Ewing, New Jersey. The company employs approximately 5,550 people and trades on the NYSE. Its portfolio spans household care, personal care, sexual wellness, diagnostics, oral care, and specialty products.
The portfolio includes ARM & HAMMER, OxiClean, Batiste, Waterpik, TheraBreath, Hero, Touchland, Trojan, First Response, Nair, Orajel, XTRA, Zicam, and specialty animal and food productivity products. Seven power brands account for about 70% of sales and profits, creating a focused model with meaningful brand concentration.
Consumer Domestic is the central earnings engine. Organic sales increased 5.4% in Q1 2026, led by TheraBreath, ARM & HAMMER, Hero, and OxiClean. ARM & HAMMER laundry consumption rose 4.1% against category growth of 2.7%, while ARM & HAMMER cat litter consumption increased 6.8% and share reached 24.6%.
Consumer International delivered 3.7% organic sales growth in Q1 2026. TheraBreath, Hero, and Batiste led growth, while lower Middle East regional sales reduced the result. Management maintains an approximate 7% organic sales growth outlook for international operations in 2026, described as softer because of the Middle East situation.
The Specialty Products Division generated $299M of revenue in 2025 and delivered 3.1% organic sales growth in Q1 2026. The division supplies animal and food productivity products, sodium bicarbonate, and cleaning and deodorizing products. Management maintains an approximate 5% organic sales growth outlook for SPD in 2026.
The segment mix has a clear strategic direction: domestic brands provide scale, international operations provide expansion, and specialty products add a business-to-business channel. The 2025 exits of VMS, Flawless, Spinbrush, and Waterpik showerhead also narrowed the portfolio toward businesses management identifies as higher-priority growth assets.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
ARM & HAMMER remains CHD's broadest flagship. Its laundry detergent, cat litter, baking soda, and deodorizing products benefit from a value position that management described as about half the price of the leading laundry detergent. Laundry share reached record levels in Q1, even as CHD reduced promotional activity relative to competitors.
The ARM & HAMMER Baking Soda Fresh laundry product contains 10 times the amount of baking soda and received a 4.9 consumer rating compared with an average portfolio rating of 4.5. Laundry sheets consumption rose 30%, giving the brand a format that fits convenience-oriented shopping and online distribution.
TheraBreath is the clearest personal-care growth driver. Its mouthwash share increased 3.5 points to 24.1%, reinforcing its number two position in total mouthwash. Household penetration remains below 20%, and the TheraBreath toothpaste launch had a strong early start, creating room for additional distribution and cross-category selling.
Hero remains the share leader in acne treatment and is twice the size of its next competitor, according to management. Distribution expansion, Mighty Patch Original activations, and Mighty Shield innovation drove Q1 momentum. Toppik consumption grew in the low double digits in Q1, while management stated that all-in consumption increased approximately 12% to 13% and that the brand remains positioned for full-year double-digit growth.
OxiClean is the main blemish in the flagship group. Share declined because of distribution loss and difficult comparisons with a large club retailer, although management said sales growth improved during the quarter and exceeded internal expectations.
CHD's competitive advantage is a combination of recognizable brands, focused category positions, and speed in product development and distribution. Management expects new product launches to contribute half of 2026 organic growth. That places innovation at the center of the earnings model rather than treating it as a marketing accessory.
Management reported an average 7% total distribution point lift over 13 weeks, with more recent resets closer to 10% to 11%. Those gains span laundry, litter, and personal care rather than relying on one fashionable launch. That breadth supports the view that Q1 volume growth had a commercial foundation beyond promotional spending.
CHD also moved online sales from 2% of sales in 2015 to approximately 24% of total consumer sales in Q1 2026. The company uses different pack sizes for dollar stores, clubs, and online channels, which gives the brands more flexibility as shopping patterns shift.
CHD entered 2026 with a cost-management plan built around productivity, hedging, and selective revenue management. Management cited $25M to $30M of full-year incremental inflation pressure from oil-based derivatives such as diesel, resins, and surfactants. The company entered the year about 60% hedged and intends to address the current cost level primarily through productivity rather than broad price increases.
The Q1 adjusted gross margin result demonstrates the operating response. Adjusted gross margin expanded to 46.4% despite 190 basis points of inflation and tariff costs. Productivity contributed 150 basis points, higher-margin acquisitions and portfolio actions contributed 110 basis points, and volume, price, mix, and foreign exchange supplied additional offsets.
That comment referred to the upgraded ERP system launched in April 2026. The transition adds execution risk, but the reported customer continuity and Q1 operating performance support a favorable initial assessment. Capital expenditures were $31.9M in Q1, and management expects full-year capital expenditures to equal approximately 2% of sales.
CHD operates in large, recurring consumer categories. Mordor Intelligence estimates the household cleaners market at $170.5B in 2026, reaching $213.8B by 2031 at a 4.6% CAGR. Its broader household care estimate is $202.3B in 2026, with laundry care as the largest segment and air care growing at a 6.8% CAGR.
The market is mature, but category growth is not uniform. Natural and organic alternatives are growing at a 6.4% CAGR through 2031 in the cited household-cleaners research, while premium air-care products are growing faster than the broader household-care market. CHD's ARM & HAMMER innovation, TheraBreath expansion, and Hero acne products align with the market's value, efficacy, convenience, and premiumization themes.
Digital commerce is another structural change. CHD's 24% online consumer-sales mix shows that the company has moved beyond a traditional shelf-based model. Gartner's 2026 survey found that 31% of U.S. consumers were willing to let AI narrow choices for household supplies, while 11% were willing to let AI make the purchase decision. The result favors trusted brands with strong product ratings and clear value propositions.
Like what you're reading?
Get full access to AI-powered research reports, market analysis, and portfolio tools.
CHD serves consumers buying everyday household, personal-care, oral-care, sexual-wellness, diagnostic, and pet-related products. Its customer base includes supermarkets, mass merchants, wholesale clubs, drugstores, convenience stores, home stores, dollar stores, pet stores, specialty retailers, websites, and other e-commerce channels.
The portfolio reaches both value-oriented and premium customers. ARM & HAMMER laundry and cat litter address consumers focused on efficacy per dollar, while TheraBreath, Hero, Touchland, and Toppik target problem-solving or premium personal-care needs. This balance mattered in Q1, when management described the consumer as pressured by inflation and borrowing costs but still resilient.
Channel behavior also differs by product. Management reported that Toppik performed well in clubs and on Amazon, while CHD's broader portfolio gained distribution across all classes of trade. Product ratings reinforce the digital proposition: ARM & HAMMER Baking Soda Fresh scored 4.9 compared with a 4.5 average across the portfolio cited by management.
CHD competes with different companies in each category. The 2025 10-K names Procter & Gamble (PG), Clorox (CLX), Colgate-Palmolive (CL), S.C. Johnson, Nestlé, Haleon, Henkel, Reckitt, Kenvue, Bayer, Pfizer, Unilever, Sanofi, Edgewell, GOJO, LifeStyles, and Philips among the competitive set, along with private-label products.
In laundry and home care, CHD faces PG, CLX, Henkel, Unilever, S.C. Johnson, and retailer brands. In oral care and water flossing, the competitive field includes CL, Haleon, Kenvue, Philips, and private label. Hero competes in acne care, while Trojan and First Response compete against Kenvue, Reckitt, LifeStyles, Bayer, and other branded and private-label products.
CHD's advantage is category focus and niche leadership rather than the broad scale of PG or Unilever. Its disadvantage is that larger competitors have greater financial resources for advertising, promotions, technology, and distribution. The portfolio concentration also matters: seven power brands generate about 70% of sales and profits, so a share loss in one major brand can carry more weight than it would inside a larger conglomerate.
Private label is a specific risk. The 2025 filing linked the VMS impairment to market-share decline and competition from new entrants, including private label. That episode shows that CHD's brand moat is strong in selected categories, not equally strong across every product.
The Q1 2026 earnings call identified inflation, borrowing costs, and Middle East geopolitical uncertainty as pressures on consumers and operating costs. Management used a $95 to $100 per barrel oil assumption and estimated $25M to $30M of full-year commodity and transportation pressure related to the Middle East situation.
The pricing stance protects volume and brand value at the current cost level, but it places greater importance on productivity and promotional discipline. Management described a three-year productivity project pipeline and said revenue-management actions would precede broader pricing if the cost pressure became materially larger.
The consumer backdrop creates a split outcome. Value brands such as ARM & HAMMER laundry and cat litter have gained share while competitors increased promotions, supporting CHD's defensive positioning. Premium brands such as TheraBreath and Hero provide mix and innovation upside, but those categories remain exposed to trade-down and private-label competition.
Debt is manageable but still a watch item, with the report pointing to leverage and commodity exposure as part of the reason CHD only earns a B on balance sheet health.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Q1 2026 net sales rose just 0.2% to $1.47B, but organic sales climbed 5.0% and adjusted gross margin expanded 130 basis points to 46.4%.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Management reaffirmed 2026 organic sales growth of 3% to 4% and adjusted EPS growth of 5% to 8%, while analysts see EPS rising from $4.04 in 2027 to $4.78 in 2030.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →CHD trades at 32.8x trailing earnings, 26.5x forward earnings, and a 3.1 PEG ratio, which keeps the valuation grade at C+ despite strong brand quality.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →The report’s $100 fair value sits below the $103.84 consensus target, with the gap reflecting strong execution offset by modest reported growth and a rich multiple.
Unlock the full analysis
Premium members get the complete breakdown — pick rationale, financial metrics, and recent earnings detail.
Get Full Access →Church & Dwight (CHD) is executing better than its modest reported revenue growth suggests. Q1 2026 delivered 5.0% organic sales growth, 4.4% adjusted EPS growth, a 46.4% adjusted gross margin, and broad distribution gains. ARM & HAMMER, TheraBreath, Hero, and Toppik provide multiple product-level growth avenues, while the value portfolio gives CHD defensive relevance when consumers feel pressured.
The investment case is not a bargain story at the current valuation framework. CHD carries meaningful debt, a 3.1 PEG ratio, private-label exposure, and sensitivity to oil-based inputs and transportation costs. The $100 fair value estimate supports a Hold recommendation: the business earns a premium for quality, but the share price needs a more favorable entry point before the upside becomes compelling for a moderate-risk, medium-term investor.
Get AI-powered research reports, daily market intelligence, and a personal analyst in your pocket.
Get Full Access →Not ready to subscribe? ·
Cancel anytime
Church & Dwight Co., Inc. (CHD) gains despite an EPS miss, as revenue topped estimates and the quarter showed resilient demand, margin pressure, and a constructive outlook. This deep-dive examines the earnings mix, cash flow trends, cost headwinds, and management’s guidance for organic sales and adjusted EPS growth.
Church & Dwight Co., Inc. (CHD) gains 0.4% even after earnings misses, as investors weigh the latest results against the stock’s modest move higher.
PFGC's selloff looks disconnected from broad-based volume growth and improving EBITDA, making the stock more attractive than USFD despite its premium earnings multiple. Thin margins and a recent EPS miss demand discipline, but the operating rebound is real.